Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.
Calcium supplements, antacids, and other products
that contain aluminum, magnesium, or iron may reduce absorption of ibandronate.
Ibandronate should be administered at least 60 minutes before administration of
any oral medication, including medications containing iron, aluminum, magnesium,
Patients should wait at least 60 minutes after taking ibandronate
before taking other oral medications. The occurrence of irritation in the
intestines may increase if
aspirin and other
anti-inflammatory drugs (NSAIDs), for example, ibuprofen (Motrin),
Advil, naproxen (Aleve) are combined with ibandronate.
PREGNANCY AND BREASTFEEDING SAFETY:
Bisphosphonates have been shown to cause fetal harm in
animals, but there are no data on risk to the fetus in humans. Ibandronate
should be used during
pregnancy only if the physician feels that its potential
benefit justifies the potential risk to the fetus.
Ibandronate is secreted into the
breast milk of
animals. It is not known whether it is secreted into human breast milk. Since
most medications do appear in human breast milk, it is generally recommended
that caution be exercised when ibandronate is given to women who are